Market Research Report
Rabies Vaccine Market - Growth, Trends, and Forecasts (2020 - 2025)
|Published by||Mordor Intelligence LLP||Product code||704728|
|Published||Content info||114 Pages
Delivery time: 2-3 business days
|Rabies Vaccine Market - Growth, Trends, and Forecasts (2020 - 2025)|
|Published: June 1, 2020||Content info: 114 Pages||
Rabies is a viral disease spread by the bite or scratch of an animal, however, the symptoms appear relatively slowly. In such cases, by the time, the symptoms appear, it is generally too late to save the patients. In the developed markets, the cases of human rabies are less because of more pet-friendly communities and government initiatives, however, in emerging markets as well as low-income countries, there are fewer regulations to protect the people against animals bites and a large number of stray dogs can be observed across metropolitan cities as well as other cities and towns. Such factors raise concerns regarding low protection against dog bites which raises the demand for rabies vaccines in such regions. However, limited resources, as well as negligence by government general public, are among the major causes which limit the use and adoption of rabies vaccines.
The Purified Chick Embryo Cell Rabies Vaccine is Expected to Show Better Growth
The purified chick embryo cell vaccine is used to protect people from post-exposure or pre-exposure. The veterinarians who are in contact with animals, such as cats, dogs, foxes, skunks, raccoons, bobcats, coyotes, and bats are more likely to be exposed to the rabies virus, leading to rising cases of rabies. Purified chick embryo cell rabies vaccines are prepared with the help of primary chick embryo cells derived from specific pathogen-free (SPF) eggs. It consists of purified and concentrated rabies virus antigen, inactivated with B-propiolactone. This vaccine acts by exposing a small dose of rabies virus to the patient in order to develop immunity to the disease. This vaccine can be used for post-exposure or pre-exposure. Such factors drive its importance and usage across hospitals and clinics.
North America is Estimated to Have Largest Share in the Global Market
According to the data published by Centers for Disease Control and Prevention (CDC) in the United States, wild animals accounted for 92.4% of the rabies cases, whereas domestic animals accounted for 48.7% cases of rabies. In the past few years the number of human deaths attributed to rabies in the United States has declined due to two major reasons, first one is animal control and vaccination programs. Secondly, effective human rabies vaccines and immunoglobulins have been developed over time. Similarly major steps were taken across Canada and Mexico to protect the animals and humans rabies virus infection spread. Significant contribution by government and companies interests in this regions, makes this region, highly useful in terms of demand and use of rabies vaccines.
The major market players are focusing on technological advancements and pet care initiatives in collabroation with hospitals and government channels. Some of the major players in the market are Zoetis Inc., Merck & Co Inc, Sanofi SA, Elanco, Virbac, etc.